Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
EyRIS logo — Revolutionizing the detection of chronic diseases

EyRIS

Revolutionizing the detection of chronic diseases

Founded 2018 Singapore Singapore 14 employees AI, Health Care

General Information

Company Name EyRIS
Founded Year 2018
Location Singapore Singapore
Employees 14
Industries AI, Health Care
Social

BounceWatch is an independent company data service, not affiliated with EyRIS. To contact EyRIS, visit eyris.io.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does EyRIS compare?

A PDF of EyRIS and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting EyRIS soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About EyRIS

EyRIS is a Singapore-based startup that aims at revolutionizing the detection of chronic diseases with its AI Deep Learning System (DLS). The DLS is a breakthrough in machine learning technology, utilizing representation-learning methods with multiple levels of representation to process natural data in their raw form, recognizing intricate structures in high-dimensional data. The company's first DLS solution focuses on automated image analysis for eye diseases such as diabetic retinopathy with an add-on for glaucoma suspect and age-related macular degeneration, and also provides teleophthalmology services through partnerships. Founded in 2018, EyRIS has the potential to contribute significantly to the healthcare industry, particularly in the field of chronic disease detection. However, further information about the industries it operates in and its recent investment activities would provide a more comprehensive understanding of its current standing and potential for growth.

Business keywords: AI Deep Learning System, Chronic disease detection, Machine learning technology, Automated image analysis, Teleophthalmology, Diabetic retinopathy, Glaucoma suspect, Age-related macular degeneration

No funding data available for EyRIS yet.

EyRIS Alternatives & Competitors

View All Alternatives
EyRIS vs
eye2you
eye2you Germany

Eye care everywhere

Pre-Seed
2 employees
AI, Digital Health
EyRIS vs
RetinAI
RetinAI Switzerland

Improving R&D of first-in-human drug candidates in pharma. Supercharging clinical trials. Elevating...

Series B
43 employees
AI, Computing
EyRIS vs
Spect
Spect United States

Our mission is to prevent blindness

Seed
19 employees
AI, Health Care
View all alternatives

FAQ About EyRIS

Revolutionizing the detection of chronic diseases
EyRIS was founded in 2018.
EyRIS is headquartered in Singapore.
EyRIS operates in AI and Health Care. Its work centres on AI Deep Learning System, Chronic disease detection, Machine learning technology and Automated image analysis.
EyRIS has approximately 14 employees.
Top alternatives and competitors to EyRIS include eye2you, RetinAI, Spect, EyeCheckup - early diagnosis, Eyenuk, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EyRIS and eye2you are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for EyRIS, https://bouncewatch.com/company/eyris, updated 31 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes